Senate Judiciary Committee Considered Key Bills to Support IP Rights and Encourage Patent Investment
As Congress returned to Washington, the Senate Judiciary Committee held a full committee hearing to consider a number of critical bills...
top of page
NEWS
Oct 9
New Report Provides Critical Context to Government Claims of IRA So-Called Drug Savings and Explores the Law’s True Impact on Patient Costs
New research from the IQVIA Institute for Human Data Science further confirms what We Work For Health (WWFH) and others have warned...
Sep 30
Recognizing the Hatch-Waxman Act’s 40th Anniversary on Capitol Hill
The Drug Price Competition and Patent Term Restoration Act, more commonly known as the Hatch-Waxman Act, profoundly changed the...
Sep 16
Fact Checking the Inflation Reduction Act’s Real-World Impact and Consequences
As healthcare access and costs continue to dominate political conversations, the flaws in the Inflation Reduction Act are becoming...
Sep 8
Hatch-Waxman Act: Celebrating 40 Years of a Balanced and Innovative Drug Ecosystem
In 1984, the Hatch-Waxman Act – formally known as the bipartisan Drug Price Competition and Patent Term Restoration Act – established a...
Sep 4
Watch: California leaders highlight biopharma innovation, collaboration and policy progress
During a recent We Work For Health roundtable with California Rep. Scott Peters, leaders across patient advocacy, biopharma, labor,...
Aug 27
Policymakers: Protect & Maximize U.S. Intellectual Property for Biopharma Innovation that Helps Patients
American innovation depends on a strong, robust intellectual property system that allows health care advances to save and enhance lives....
Aug 26
State-By-State Data Showcases Biopharma’s Impact on Local Economics and Innovation
We Work For Health recently unveiled a new set of one-page resources designed to highlight the significant impact of the...
Aug 21
Protecting the Drug Discovery Pipeline
A version of this blog originally published as an op-ed in The Center Square in Arizona. We're sharing it here with additional updates...
Aug 13
A Guide to Understanding the Administration’s Announcement on Medicare Drug Pricing
The Biden administration this week is expected to claim victory on its stated goal of lowering drug prices for seniors. While the...
Aug 6
10 Reasons Biopharma Innovation Needs Strong IP Protections
By Dan Leonard, WWFH Executive Director Intellectual property (IP) plays a crucial role in the success of the pharmaceutical and biotech...
Jul 29
Inflation Reduction Act Causes Medicare Part D Premiums To Increase Again
On Monday, the Centers for Medicare and Medicaid Services (CMS) announced 2025 premiums for Medicare Part D plans will increase again....
Jun 28
New Research Shows Alarming Drop in Neurology Innovation Due To IRA’s Small Molecule ‘Pill Penalty’
During an event on Capitol Hill this week, California Rep. Scott Peters highlighted a graphic that clearly illustrates the distorted...
Jun 24
New Report Demonstrates How the IRA’s “Pill Penalty” is Setting Back the Development of Non-Opioid Pain Medicine
Despite the significant demand for effective non-opioid medications for the treatment of pain, a recent report from the Pioneer Institute...
Jun 24
We Work For Health Honors Rep. Scott Peters with Healthcare Leadership Innovation Award
SAN DIEGO – At a We Work For Health roundtable on June 20, the organization and its partners honored Rep. Scott Peters (CA-50) with the...
Jun 20
As NIST Finalizes March-in Guidance, Innovation Community Continues to Convey Opposition
The National Institute of Standards and Technology (NIST) may soon finalize its controversial proposal to expand the scope of the...
Jun 4
The Inflation Reduction Act is Hurting Medicare Access and Increasing Patients’ Costs
This week, the largest not-for-profit health insurance provider in Missouri, Blue KC, announced it will leave the Medicare Advantage...
Apr 30
CMS Finalizes Policy to Facilitate Faster Biosimilar Uptake but Follow-on Policies and Actions Still Needed
The Centers for Medicare & Medicaid Services (CMS) recently released a final rule allowing Medicare Advantage and Part D health plans to...
Apr 2
Commonsense Policies Needed to Lower Healthcare Costs and Improve Patient Access While Protecting Drug Development Pipeline
Today, President Biden highlighted the administration’s current and future efforts to lower healthcare costs. The good news is recent...
Mar 11
Vendors Power America's Biopharmaceutical Industry
We Work For Health recently released new employment, vendor and supplier expenditure data that showcases the vital contributions of these...
bottom of page